The Vertiginous Revelations of “You Can See Everything”

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-10-09T12:06:39.933Z • Permanent link

Elizabeth Holmes, the disgraced founder of Theranos, is at the center of a stormy interrogation by Nathan Fielder and Lance Oppenheim. The full story is complex, with many threads to unravel. Holmes, a Stanford University dropout, had promised to revolutionize the healthcare industry with her revolutionary blood-testing technology. She claimed that her company, Theranos, had developed a machine that could perform hundreds of tests using just a few drops of blood, a fraction of the cost and time of traditional methods.

Theranos had attracted significant attention from investors, including prominent figures such as Larry Ellison and Betsy DeVos, as well as the US government. The company had even secured a deal with Walgreens to offer its blood-testing services in over 1,000 stores. However, it was all a facade. In reality, Theranos' technology was a far cry from Holmes' claims, and the company was hemorrhaging money. By 2015, Theranos was burning through $140 million per year, and its valuation had plummeted to just $9 billion. The US government was starting to take notice, with the Securities and Exchange Commission (SEC) launching an investigation into the company's financial dealings.

In 2018, it all came crashing down. The Wall Street Journal published a scathing exposé, revealing that Theranos' technology was not as revolutionary as claimed. The company's CEO, Elizabeth Holmes, was subsequently fired, and the company's valuation was reduced to just $9 billion. Holmes was subsequently charged with wire fraud and conspiracy. The full story is one of hubris, deception, and the dangers of unchecked ambition.

The revelations surrounding Theranos have significant implications for the Data Sources domain. Companies such as LabCorp and Quest Diagnostics, which had partnered with Theranos to offer its blood-testing services, are now facing a major backlash. Many investors have also lost millions of dollars, and the reputations of prominent figures such as Larry Ellison have been tarnished. The incident has also raised questions about the lack of regulation in the healthcare industry, particularly when it comes to the rapid development and deployment of new technologies.

The Theranos scandal has also highlighted the dangers of "fake it till you make it." The company's culture of deception has sent shockwaves through the industry, and many are now calling for greater transparency and accountability. The incident has also raised questions about the role of data in the healthcare industry, particularly when it comes to the use of artificial intelligence and machine learning. As the industry continues to evolve, it is essential that we learn from the lessons of Theranos and prioritize accuracy, transparency, and accountability.

The Theranos scandal is not an isolated incident. There have been numerous other examples of companies making false claims about their technology, particularly in the healthcare and technology industries. The rise of "fake news" and disinformation has also created a culture of skepticism, where companies are no longer willing to make bold claims about their products. This has led to a backlash against companies that make exaggerated or false claims, and a renewed focus on transparency and accountability.